| |
 |
| Printer
Friendly |
 |
| |
| Our Scientific Advisory
Board of recognized experts and thought-leaders from industry
and academia has representatives from the USA, Europe, and the
Far East. Their expertise, experience, and knowledge cover informatics-related
disciplines of relevance in drug discovery and development,
including leading-edge research and industrial applications.
They advise senior management on advances in science and
technology, and comment on strategic direction. |
| |
 |
| |
|
|
|
 |
|
Prof. Russ B. Altman |
|
| Prof. Altman is professor of medicine (medical informatics) and professor of computer science (by courtesy) at Stanford University, associate director of the Stanford Medical Scientist Training Program, and a Board-certified practitioner of internal medicine. His academic honors include being named a Stanford Hume Faculty Scholar and receiving both the Annual Young Investigator Award (Western Society of Clinical Investigation) and the American College of Medical Informatics Award, all in 1998. In 2000 he received the Stanford Medical School Award for Excellence in Graduate Teaching. Beginning with a primary interest in bioinformatics, Altman is particularly interested in techniques for representing biological knowledge (not just data) for collaborative and automatic scientific computation. He is working on representing the contents of the scientific literature (particularly with regard to pharmacogenomics and the structure of the bacterial ribosome) to support the development of robust models of biological systems. He is also interested in novel user interfaces to biological data and computational architectures supporting scientific collaboration. Altman holds a Ph.D. from the Stanford Program in Medicine Information Sciences (1989) and an MD from the Stanford Medical School (1990). |
| Top |
| |
|
| |
 |
|
Prof. Dr. Mikael Dolsten |
|
| Dr. Dolsten is Head of Corporate Division Pharma Research/Discovery at Boehringer Ingelheim with responsibility for approximately 1400 discovery scientists and world-wide research in respiratory, immunology/inflammation, metabolic disease, CNS/pain, oncology and cardiovascular therapies. After earning an M.D. from the University of Lund and Lund University Hospital, Sweden, Dr. Dolsten received his Ph.D. in 1988 and was appointed Associate Professor (1989) and Adjunct Professor in Cell and Molecular Biology (1996) at Lund University. The author of some 150 scientific articles and book chapters, Dr. Dolsten has spent approximately seventeen years in the pharmaceutical Industry. He has held various senior R&D management positions including: Head of Preclinical Research Oncology/Immunology at Pharmacia & Upjohn, Lund, and Head of Preclinical R&D, Vice President of Respiratory and Inflammation at Astra Draco, Lund. Before joining Boehringer Ingelheim in 2003, Dr. Dolsten was responsible for integrating several areas of AstraZeneca Discovery post-merger; he also served as Global Vice President/Head of Cardiovascular/Metabolic & Gastrointestinal Discovery at AstraZeneca, directing the work of over 750 scientists at research sites in Sweden and the UK.
|
| Top |
| |
|
| |
 |
|
Prof.
Dr. Johann Gasteiger |
|
| Prof. Gasteiger is professor with the
Institute for Organic Chemistry and co-founder of the Computer-Chemistry-Center
at the University of Erlangen in Nuremberg, Germany. His research
interests include informatics techniques for organic reactions,
visualization, and spectroscopy. He has undertaken numerous
professional activities with the German Chemical Society and
the Federation of European Chemical Societies, has consulted
with many informatics suppliers and discovery companies, and
serves on several editorial boards. He is the 1991 recipient
of the Gmelin-Beilstein Medal presented by the German Chemical
Society for achievements in computer chemistry and the 1997
Herman Skolnik Award presented by the Division of Chemical Information
of the American Chemical Society. Prof. Gasteiger has a Ph.D.
from the University of Munich (1971). |
| Top |
| |
|
| |
 |
|
Dr.
James Golden |
|
|
Dr. Golden is Chief Technology Officer of SAIC's Life Sciences Office. Previously he has held positions in market intelligence, business development and informatics at Life Science Insights, 454 Corporation, CuraGen, GeneSys Technologies, and Pioneer Hi-Bred. He is a Major in the U.S. Air Force Reserve and spent several years on the staff of the Air Force Test Pilot School. Dr. Golden has a B.S. in mathematics and computer science from Rhodes College, Memphis, TN; an M.S. in computer science from the University of Tennessee Space Institute in Tullahoma, TN; and a Ph.D. in mechanical engineering from Vanderbilt University (design and optimization of DNA sequencing devices).
|
| Top |
| |
|
| |
 |
|
Dr.
Joseph Guiles |
|
| Dr. Guiles is currently the Director of
Chemistry at Replidyne, an anti-infective drug discovery company
in Louisville, Colorado. Over the last twelve years he has worked
in the lead discovery and optimization phases of drug discovery,
holding a number of technical and managerial roles within Chemistry.
For the last five years at Aventis Pharmaceuticals he established
the High Throughput Medicinal Chemistry Department and a global
team that defined the composition of the Aventis compound screening
collection used for HTS. The work of this team is internationally
recognized for pioneering work in microwave assisted synthesis.
Prior to Aventis Dr. Guiles helped establish the combinatorial
chemistry team of R.W. Johnson Pharmaceutical Research and the
Hit-To-Lead Chemistry team at Sterling Winthrop. Both of these
teams were established during the formative years of combinatorial
chemistry and high throughput screening. Dr. Guiles earned his
Ph.D. in Chemistry at Colorado State University in 1990. His
research focus covers medicinal, organic, and combinatorial
chemistry and he has authored or co-authored a total of 29 papers
and patents. He is currently a member of one scientific advisory
board and one editorial board. |
| Top |
| |
|
| |
 |
|
Dr. John H. McDonald III |
|
| Dr. McDonald is currently Director, Biology Operations, leading biology strategy development and IT strategic planning for the Discovery Biology component of Lilly Research Laboratories. He has served multiple scientific and administrative roles since joining Lilly in 1983. After his initial years as a medicinal chemist concentrating on carbacephalosporins, his focus changed to diabetes, where he led the medicinal chemistry effort responsible for the PKCß inhibitor, ruboxistaurin, currently in phase III clinical trials for diabetic microvascular complications. A second compound from this effort, enzastaurin, has recently entered phase III studies for lymphoma and glioblastoma. His career shifted to drug discovery strategy as he helped rebuild the chemistry organization and refocused it on a phased approach to drug discovery. In 2000 Dr. McDonald joined the leadership of the Cancer Discovery organization in biology where he helped to establish its current strategic direction. This led to his role overseeing biology strategy. Dr. McDonald brought one of the first chemistry computation tools to LRL, Prof. Still's Model, and has been actively involved in the utilization of IT tools in drug discovery up to his present role, building an IT strategy for the discovery biology organization. Dr. McDonald received his B.S. in chemistry from Indiana University and his doctorate from Columbia University. |
| Top |
| |
|
| |
 |
|
Dr.
Berta Strulovici |
|
| Dr. Strulovici is executive director of
basic research, automated biotechnology at Merck & Co. From
1985 to 1992 she was a senior scientist at Syntex Corp. in Palo
Alto, CA, where she worked in several therapeutic areas. From
1992 to1996 she was director of molecular pharmacology at Tularik,
Inc. in South San Francisco, where she established a state-of-the-art
high-throughput screening (HTS) facility. Dr. Stulovici joined
Merck in 1996 where she established an automated biotechnology
department with the specific mandate to build an ultra high-throughput
screening (uHTS) operation. Today this department supports Merck’s
global materials research laboratory in the areas of HTS and
uHTS. Dr. Strulovici received her Ph.D. from the Weizmann Institute
of Science in Israel and was a postdoctoral fellow with Prof.
Robert J. Lefkowitz at the Howard Hughes Institute, Duke University
Medical Center, Durham, N.C. |
| Top |
| |
|
| |
 |
|
James
Summers, Ph.D. |
|
Dr. Summers joined Abbott in 1983 and currently
serves as divisional vice president, advanced technology. His
area of responsibility includes technologies that enable and
accelerate drug discovery, including genomics, high throughput
screening, combinatorial chemistry, structural biology, structural
chemistry and automation engineering. Summers has held various
positions at Abbott within the immunologic disease and cancer
research areas, including director of inflammation research.
He has participated in or led programs that resulted in several
drug development candidates, including the antiasthma drug Zyflo.
Summers earned a bachelor of science degree in chemistry from
Denison University and a doctorate in organic chemistry from
Harvard University.
|
| Top |
|
|
|
|
